Dublin, Oct. 10, 2017 -- The "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome.
TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described. A section on drug abuse describes methods of detection of performance-enhancing drugs.
TDM market is analyzed from 2016 to 2026 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2016 to 2026 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed.
The report contains profiles of 35 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 21 tables, 9 figures and 210 selected references from literature.
Benefits of this report
- Up-to-date one-stop information on therapeutic drug monitoring
- Description of 35 companies involved with their collaborations in this area
- Market analysis 2016-2026
- Market values in major regions
- Strategies for developing markets for therapeutic drug monitoring
- A selected bibliography of 210 publications
- Text is supplemented by 21 tables and 9 figures
Who should read this report?
- Biotechnology companies developing assays and equipment for drug monitoring
- Reference laboratories providing drug monitoring services
- Pharmaceutical companies interested in companion tests for monitoring their drugs
- Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine
Key Topics Covered:
Executive Summary
1. Introduction
2. Technologies for TDM
3. Drug Monitoring Instruments
4. Applications of TDM
5. Drugs Requiring Monitoring
6. Monitoring of Biological Therapies
7. Monitoring of Drug Abuse
8. Markets for TDM
9. Companies
10. References
For more information about this report visit https://www.researchandmarkets.com/research/hzksfx/therapeutic_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Instagram Outage Disrupts Thousands of U.S. Users
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Washington Post Publisher Will Lewis Steps Down After Layoffs
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



